The Botnar Institute of Immune Engineering (BIIE) is a new interdisciplinary research institute dedicated to innovation in immune engineering. Founded in 2024 through a generous endowment from Fondation Botnar, the BIIE supports scientists in taking on
ARTIDIS AG is a clinical-stage health-tech start-up founded in Basel, Switzerland, that has developed the first nanomechanical biomarker for cancer diagnosis and treatment optimization. The ARTIDIS nanotechnology platform integrates different types of clinical data into the
The Botnar Institute of Immune Engineering (BIIE) is a new interdisciplinary research institute dedicated to innovation in immune engineering. Founded in 2024 through a generous endowment from Fondation Botnar, the BIIE supports scientists in taking on
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)